💸 The Tape

The Global Cannabis Regulatory Summit published its 2026 white paper collection this week, the formal record of a London gathering that drew participants from nearly 30 countries and 20 regulatory jurisdictions. It's a dense document — thirteen papers, three funding proposals, and a keynote from Canadian Senator Tony Dean — but the through-line is simple enough to fit on an index card. The legalization argument is over in the places that matter. The next decade is implementation, and implementation is where cannabis policy has been failing.

Here's what the paper actually says, what it's asking for, and how to read it.

The three pillars

The organizing framework, laid out by ASTM D37 chair David Vaillencourt and Artemis's Hilary Black, holds that credible cannabis markets need three things working together: agreed technical standards, market responsibility mechanisms, and a pathway to regulatory alignment across borders. Each has an institutional sponsor. Standards run through the S3 Collective and ASTM Committee D37. Responsibility runs through a proposed Global Cannabis Responsibility Alliance. Alignment runs through the Cannabis Medicines Regulatory Accord, a new body designed to help countries interpret the UN drug conventions consistently rather than reinvent medical frameworks one at a time.

The diagnosis underneath is blunt. Every country operates under the same 1961 Single Convention and has built something different anyway. Licensing, prescribing, quality, oversight and patient access vary so widely that a product legal in one pharmacy market can't clear customs in the next. The paper's position is that treaty reform isn't the answer — the treaties already permit medical use — and that the missing piece is the unglamorous work of building systems that function predictably across jurisdictions.

How fragmented is it, really?

The standards workshop ran a pre-summit survey across regulators, operators, clinicians and investors on five continents, rating eleven standards domains on a red-yellow-green scale. More than 90% of all responses came back yellow or red. Only three topics received a green rating at all, each from a single respondent. Standards of care — what physicians are actually supposed to do with cannabis — was rated red by 74%, the worst score on the board. Product standards, marketing and point-of-sale frameworks each drew red from a majority. Nearly four in five respondents said aligned terminology was critical, and nearly half said standards can't function without definitions that don't yet exist.

That's the practitioners' own assessment of their field, and it's the most useful data point in the document.

Standards move faster than law — if someone writes them

The paper's strongest practical case is the standards lifecycle. ASTM D8197, the water-activity specification for cannabis flower, went from a voluntary consensus standard in 2018 to codification in NIST handbooks and U.S. weights-and-measures law. ASTM D8441, the intoxicating-cannabinoid warning symbol, took about twelve months from concept to publication and is now used in nine U.S. states, royalty-free. Under the National Technology Transfer and Advancement Act in the U.S. and Regulation 1025/2012 in Europe, agencies are directed to prefer voluntary consensus standards over government-unique rules — which means the pathway from ASTM document to enforceable law is well-worn.

The economic argument is concrete. Lab data from one major producing jurisdiction showed average finished flower at roughly 0.40 water activity, well below the standard range, which the paper models at about $27 million in foregone producer revenue and $5 million in lost state tax in a single state from over-drying alone. Quality and margin point the same direction. The next fight is an intended-use classification framework — medical, wellness, adult-use — and the "wellness" category generated the most heated exchange of the summit, with physicians warning it normalizes self-medication and operators pointing out it already describes most of the market.

Responsibility infrastructure, or the alternative

The responsibility workshops, run by Potash Global Strategy, tested one proposition: when market growth outpaces responsibility infrastructure, governments respond with broad restrictions that hit the whole sector, not just the bad actors. Two case studies made the point — German telemedicine access and the U.S. hemp-derived THC market, with its copycat packaging and gas-station distribution. Both produced backlash, and the backlash in Washington is now a federal ban with a December 11 effective date.

Participants were skeptical of a full self-regulatory organization — too early, too expensive, too easy to evade by shutting down and restarting. But they converged on a modular approach: start with practical standards in one or two markets, build regulator engagement, and tie certification to things that actually change behavior — licensing, insurance, banking, and market access — rather than association membership or fines. The paper names Germany, the U.S. and Canada as candidate pilot markets and proposes a lean first-year proof of concept for the Alliance.

The rescheduling chapter

Schedule III landed after the summit, so the organizers commissioned a stand-alone analysis from Vicente LLP's Shawn Hauser and Andrew Livingston on the U.S., and Oppenhoff's Franziska Katterbach on Europe. It's the section most readers will skip to, and it's the one with the sharpest operational guidance.

The U.S. analysis confirms what operators already know: medical-only licensees get 280E relief and the advertising-crime removal; adult-use stays Schedule I; dual-license operators must segregate revenue and expense to capture any benefit. The more interesting content is on trade. The DOJ Final Order amended DEA import/export regulations to cover state-licensed medical cannabis, creating a theoretical gateway to international commerce — but state licenses still prohibit it, the FDA still treats the product as an unapproved new drug, and every handler in the chain needs its own DEA registration. The authors argue state-level trade barriers are "highly vulnerable" to Dormant Commerce Clause challenges and expect interstate commerce to arrive by litigation before legislation.

Their seven-point playbook for MSOs is explicit: segregate medical from adult-use assets, because international acquirers will only touch Schedule III-clean operations; upgrade to cGMP and EU-GMP, because state compliance doesn't travel; secure expedited DEA registration; prepare supply chains for interstate borders falling; and position for refinancing at lower rates and 280E refund claims. Trulieve's medical ring-fence and NYSE listing is the template the paper describes without naming.

Katterbach's European view is the quieter and arguably more important one. Europe's medical markets were built inside pharmaceutical and narcotics frameworks — physician prescribing, pharmacy dispensing, EU-GMP, pharmacovigilance — which means they're already more compatible with international trade than most of the American state-market system. Her forecast is that Schedule III accelerates the "pharmaceuticalization" of the industry and sends U.S. capital into European GMP infrastructure and partnerships rather than U.S. product into European pharmacies. Germany, she argues, is no longer just a European market; it's the credibility test.

What the implementation panel learned

The practical regulators' session — Switzerland's Zurich pilot, Jamaica's four-year rule revision, U.S. state programs and Canada's medical framework — produced the paper's most quotable advice. Build revision authority into the legislation so regulators can fix rules without reopening the statute. Collect baseline data before commercialization, because once license fees fund the measurement, it isn't baseline anymore. Bring the medical college into the room at the design stage, not after. And treat state programs as the federal inheritance: Schedule III implementation should standardize what state regulators built, not displace it.

Canada's five-year review gets cited as the model: no measurable change in motor vehicle accidents, a decrease in youth access, and a small rise in hospitalizations the panel attributes largely to patients now being willing to disclose use. Senator Dean's keynote made the same point about youth access that the CDC data confirmed last month — the counter is a barrier that didn't exist before.

Guidance: how to read this document

For operators, the white paper is a due-diligence checklist disguised as policy. If the next phase of value is institutional capital, index inclusion, international M&A and eventually cross-border trade, then the gating items are the ones the paper names: medical/adult-use segregation, GMP-grade manufacturing, DEA registration, participation in standards bodies, and data you can publish. Operators who treat ASTM D37 as a trade-show sideshow are leaving the technical baseline to be written by someone else.

For investors, the signal is where credibility is being priced. The paper's trade panel says competition in medical cannabis is increasingly "between systems capable of inspiring confidence," not between companies. That favors operators in pharmacy-channel markets, EU-GMP exporters, and U.S. medical-only entities, and it discounts retail-first adult-use models that can't clear a European import license.

For regulators, the ask is modest and specific: reference existing consensus standards rather than drafting from scratch, build revision into the rules, fund baseline data, and participate in the CMRA process so the next country doesn't have to relitigate the same questions.

The road ahead

Three funding proposals close the document — for the S3 Collective, the Responsibility Alliance and the CMRA — and the honest read is that the paper is a prospectus as much as a report. GCRS is asking industry to pay for the infrastructure that would make it credible, on the argument that the alternative is regulators doing it badly or not at all.

The next summit is in Zurich, April 5–7, 2027. By then the DEA will have ruled on adult-use, the hemp deadline will have come and gone, the first DEA-registered medical operators will have a year of federal compliance behind them, and the first interstate-commerce lawsuit will likely be filed. The London paper's bet is that the industry's next decade is decided by standards committees and data registries rather than ballot measures. On the evidence of the last six months, that's the right bet.

Download full paper HERE

📈 Dog Walkers

$LOVFF ( ▼ 2.63% ) and $CURLF ( ▼ 3.24% ) Strengthen Ties

Ayr Wellness (CSE: AYR.A) (OTCQX: AYRWF) closed the first transfer of its Ohio operations to Arboretum Bidco LLC on Wednesday, the latest step in a restructuring that has been dismantling the company piece by piece since last November. Arboretum is the vehicle Ayr's senior secured noteholders created to take the keys; it will keep operating under the Ayr Wellness name, and Ohio regulators signed off on the transfer before closing.

Ohio follows Virginia, Florida, New Jersey and Nevada, all of which moved to Arboretum earlier this year under the November 14, 2025 Master Purchase Agreement. What remains with the public parent is a shrinking list of assets and a stated intention to wind down the corporate entity once the transfers are complete. The press release says as much in its forward-looking language: "the wind-down of the existing AYR corporate parent entity."

The mechanics are what a lender-led restructuring looks like when there's no bankruptcy court to run it. Noteholders took the operating assets through a consensual asset purchase, state by state, with each transfer gated by regulatory approval. Equity holders are left with a shell.

Ohio is a real market, with sales running north of $100 million a month and an eight-store cap that makes existing permits valuable. For the noteholders, it's another operating asset recovered at par-plus. For Ayr shareholders, it's one more confirmation of a conclusion the market reached a year ago.

The company that once called itself a top-five MSO is now a transfer agent for its own creditors. A few more closings and there won't be anything left to transfer.

$VREOF ( ▼ 3.66% ) Finances FL and NY

Vireo Growth (CSE: VREO) (OTCQX: VREOF) closed a US$60 million real estate loan from a U.S. commercial bank and institutional lender on Monday, secured by its cultivation and production facilities in Johnstown, New York and Palatka, Florida. The rate is 8.5%, the term runs to April 2034, and the structure is a first-priority mortgage on the properties with a pledge of the holding entities — which is to say, a normal commercial real estate loan, the kind cannabis operators spent a decade being told they couldn't get.

The use of proceeds is the strategy. About $49 million refinances the senior debt Vireo took on to exercise its purchase option on the Johnstown facility, the former Vireo Health of New York campus that anchors its Registered Organization. Roughly $11 million funds the outright acquisition of the Palatka facility, which Vireo had been leasing from Rainbow Palatka FL LLC and which supplies its Green Dragon retail footprint in Florida. The Rainbow lease gets terminated and replaced with an intercompany lease to Green Dragon Florida, so the rent now flows to Vireo's own propco rather than a third-party landlord.

That's the tell. Vireo has spent eighteen months buying retail with stock; this is the company taking ownership of production infrastructure with bank debt in its two most strategically important markets — New York, where a vertical RO license is scarce, and Florida, where the medical-only program sits entirely in Schedule III and cultivation capacity is the constraint on growth.

CFO Tyson Macdonald called 8.5% "among the most attractive rates in the cannabis sector," and he's right. Compare it to Curaleaf's 11.5% secured notes, Verano's 9.5% term loan or the 15%-plus the GAO found small operators paying, and it's clear which direction institutional lenders are moving for borrowers with hard assets and medical exposure. The phrase "long-term banking partner" is the one worth underlining. Vireo just converted a landlord into a lender, at a price that would have been unthinkable in 2024.

📺 Trade To Black

Why Hemp Reform Just Got More Complicated | TDR Cannabis in 5

• GOP senators want a DOJ probe: Tom Cotton, Susan Collins, Pete Ricketts and Ted Budd asked AG Todd Blanche to investigate Chinese transnational criminal organizations in U.S. cannabis and hemp — how they're financed, how they're buying land, what chemicals they import, and any CCP ties.

• The DEA already flagged it: The 2025 National Drug Threat Assessment found these networks dominate illegal cultivation, often inside legal states, producing 25–30% THC flower with banned Chinese pesticides and undocumented labor.

• Real cases, not theory: The letter cites 7 Chinese nationals charged last year, 29 more in April in an Oklahoma-centered operation, and ongoing trafficking and toxic-pesticide issues in Siskiyou County, California.

• It's now a hemp argument: The senators blame 2018 Farm Bill loopholes for giving these networks room to operate — landing weeks before the December 11 hemp deadline and adding a national-security layer to the fight.